华因赖特再次确认"买入"评级为Vor Biopharma, 设定了$ 17.50的目标价格. HC Wainwright reaffirms "Buy" rating for Vor Biopharma, setting a $17.50 price target.

HC Wainwright重申Vor Biopharma(VOR)的“Buy”评级, HC Wainwright has reaffirmed a "Buy" rating for Vor Biopharma (VOR), setting a price target of $17.50. 其他分析师有不同的意见, 奥本海默将其目标降至10美元,而JMP证券和Wedbush则保持超越评级的目标分别为12美元和11美元. Other analysts have varied opinions, with Oppenheimer lowering its target to $10, while JMP Securities and Wedbush maintain outperform ratings with targets of $12 and $11, respectively. 协商一致价格目标是10.92美元。 The consensus price target is $10.92. 沃尔生物制药的主要产品,tremtelectogene empogeditemcel,正在急性髓性白血病的1/ 2期试验中. Vor Biopharma’s lead product, tremtelectogene empogeditemcel, is in phase 1/2 trials for acute myeloid leukemia.